Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial
- 1 October 2006
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 368 (9544), 1339-1348
- https://doi.org/10.1016/s0140-6736(06)69558-5
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trialBritish Journal of Haematology, 2005
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBlood, 2003
- Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XIBritish Journal of Haematology, 2002
- Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocolBritish Journal of Haematology, 2001
- Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997Leukemia, 2000
- Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials*British Journal of Haematology, 1995
- Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemiaLeukemia Research, 1994
- The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemiaLeukemia Research, 1994
- Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?British Journal of Cancer, 1993
- Clinical pharmacology of oral thioguanine in acute myelogenous leukemiaCancer Chemotherapy and Pharmacology, 1981